Capricor Therapeutics Announced A Registered Direct Offering Of 4.9M Shares, Each Share Was Sold With A Warrant To Purchase One Share At A Combined Price Of $4.66, With Gross Proceeds Of $23M
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics has announced a registered direct offering of 4.9 million shares. Each share was sold with a warrant to purchase one share at a combined price of $4.66, resulting in gross proceeds of $23 million.
September 29, 2023 | 11:40 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Capricor Therapeutics' direct offering of 4.9 million shares could potentially dilute existing shareholders' equity, but also provides the company with $23 million in gross proceeds.
The direct offering of shares by Capricor Therapeutics could lead to dilution of existing shareholders' equity, which might negatively impact the stock price. However, the $23 million in gross proceeds could be used for business expansion or debt repayment, which could have a positive impact on the company's financial health and potentially its stock price. Therefore, the short-term impact on the stock price is uncertain.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100